

LITERATUR

1. Coombs RPA, Gell PGH. Classification of allergic reactions responsible for hypersensitivity and disease. In: Gell PGH, Coombs RPA, editors. Clinical aspects of immunology. Oxford: Blackwell, 1975: 761-781.
2. Jackola DR, Liebeler CL, Lin C-Y, et al. Evidence that negative feedback between antibody concentration and affinity regulates humoral response consolidation to a non-infectious antigen in infants. *Mol Immunol* 2005; 42:19-30.
3. Johansson SG, Hourihane JO, Bousquet J, Brujnzeel-Koomen C, Dreborg S, Haahtela T et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. *Allergy* 2001; 56:813-824.
4. Wahn U. Allergische Erkrankungen im Säuglings- und Kindesalter. In: Heppt W, Renz H, Röcken M (Hrsg.). *Allergologie*. Berlin, Heidelberg, New York: Springer, 1998: 272-277.
5. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol* 1980; 92 (Suppl), 44-47.
6. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *N Engl J Med* 1995; 332:133-138.
7. Nickel R, Lau S, Niggemann B, Grüber C, von Mutius E, Illi S et al. Messages from the German Multicentre Allergy Study. *Pediatr Allergy Immunol* 2002; 13 Suppl 15:7-10.
8. von Mutius E. The rising trends in asthma and allergic disease. *Clin Exp Allergy* 1998; 28 Suppl 5:45-49.
9. Hopp RJ, Bewtra AK, Watt GD, Nair NM, Townley RG. Genetic analysis of allergic disease in twins. *J Allergy Clin Immunol* 1984; 73:265-270.
10. Larsen FS, Holm NV, Henningsen K. Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. *J Am Acad Dermatol* 1986; 15:487-494.
11. Sengler C, Lau S, Wahn U, Nickel R. Interactions between genes and environmental factors in asthma and atopy: new developments. *Respir Res* 2002; 3:1-7.
12. Postma DS, Meyers DA, Jongepier H, Howard TD, Koppelman GH, Bleecker ER. Genome Wide Screen for Pulmonary Function in 200 Families Ascertained for Asthma. *Am J Respir Crit Care Med* 2005.
13. Cookson WO, Moffatt MF. Asthma: an epidemic in the absence of infection? *Science* 1997; 275:41-42.

14. von Mutius E, Martinez FD, Fritzsich C, Nicolai T, Reitmeir P, Thiemann HH. Skin test reactivity and number of siblings. *BMJ* 1994; 308:692-695.
15. von Mutius E, Martinez FD, Fritzsich C, Nicolai T, Roell G, Thiemann HH . Prevalence of asthma and atopy in two areas of West and East Germany. *Am J Respir Crit Care Med* 1994; 149:358-364.
16. Bråbäck L, Breborowicz A, Julge K, Knutsson A, Riiikjarv MA, Vasar M et al. Risk factors for respiratory symptoms and atopic sensitisation in the Baltic area. *Arch Dis Child* 1995; 72:487-493.
17. von Mutius E, Weiland SK, Fritzsich C, Duhme H, Keil U. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany. *Lancet* 1998; 351:862-866.
18. Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. *J Allergy Clin Immunol* 2001; 108:516-520.
19. Gergen PJ, Turkeltaub PC, Kovar MG. The prevalence of allergic skin test reactivity to eight common aeroallergens in the U.S. population: results from the second National Health and Nutrition Examination Survey. *J Allergy Clin Immunol* 1987; 80:669-679.
20. Williams HC, Strachan DP, Hay RJ. Childhood eczema: disease of the advantaged? *BMJ* 1994; 308:1132-1135.
21. Bergmann RL, Edenharter G, Bergmann KE, Lau S, Wahn U. Socioeconomic status is a risk factor for allergy in parents but not in their children. *Clin Exp Allergy* 2000; 30:1740-1745.
22. Racioppi L, Ronchese F, Matis LA, Germain RN. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. *J Exp Med* 1993; 177:1047-1060.
23. Street NE, Schumacher JH, Fong TA, Bass H, Fiorentino DF, Leverah JA et al. Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. *J Immunol* 1990; 144:1629-1639.
24. Paliard X, de Waal MR, Yssel H, Blanchard D, Chretien I, Abrams J et al. Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones. *J Immunol* 1988; 141:849-855.
25. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 1986; 136:2348-2357.

26. Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. *J Immunol* 1986; 136:4538-4541.
27. Finkelman FD, Katona IM, Urban JF, Jr., Holmes J, Ohara J, Tung AS et al. IL-4 is required to generate and sustain in vivo IgE responses. *J Immunol* 1988; 141:2335-2341.
28. Del Prete G, Maggi E, Parronchi P, Chretien I, Tiri A, Macchia D et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. *J Immunol* 1988; 140:4193-4198.
29. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine expression in CD4 cells. *Cell* 1997;89:587-596.
30. Mond JJ, Carman J, Sarma C, Ohara J, Finkelman FD. Interferon-gamma suppresses B cell stimulation factor (BSF-1) induction of class II MHC determinants on B cells. *J Immunol* 1986; 137:3534-3537.
31. Vercelli D, Jabara HH, Arai K, Geha RS . Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. *J Exp Med* 1989; 169:1295-1307.
32. Yamaguchi Y, Hayashi Y, Sugama Y, Miura Y, Kasahara T, Kitamura S et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. *J Exp Med* 1988; 167:1737-1742.
33. Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. *Clin Exp Immunol* 1991; 85:312-316.
34. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J Exp Med* 1989; 170:2081-2095.
35. Chretien I, Pene J, Briere F, de Waal MR, Rousset F, De Vries JE. Regulation of human IgE synthesis. I. Human IgE synthesis in vitro is determined by the reciprocal antagonistic effects of interleukin 4 and interferon-gamma. *Eur J Immunol* 1990; 20:243-251.
36. Vercelli D, De Monte L, Monticelli S, Di Bartolo C, Agresti A. To E or not to E? Can an IL-4-induced B cell choose between IgE and IgG4? *Int Arch Allergy Immunol* 1998; 116:1-4.
37. Renz H. Immunologische Grundprinzipien der allergischen Entzündung. In: Heppt W, Renz H, Röcken M (Hrsg.). *Allergologie*. Berlin: Springer, 1998: 26-34.

38. Renz H. Immunologische Grundlagen allergischer Entzündung. In: Wahn U, Seeger R, Wahn V (Hrsg.). Pädiatrische Allergologie in Klinik und Praxis . München, Jena: Urban und Fischer, 1999: 119-131.
39. Busse W, Elias J, Sheppard D, Banks-Schlegel S. Airway remodeling and repair. *Am J Respir Crit Care Med* 1999; 160:1035-1042.
40. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. *Immunol Today* 1996; 17:138-146.
41. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. *Immunol Today* 1997; 18(10):478-482.
42. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. *Lancet* 1999; 353:196-200.
43. Tang ML, Kemp AS, Thorburn J, Hill DJ. Reduced interferon-gamma secretion in neonates and subsequent atopy. *Lancet* 1994; 344:983-985.
44. Williams TJ, Jones CA, Miles EA, Warner JO, Warner JA. Fetal and neonatal IL-13 production during pregnancy and at birth and subsequent development of atopic symptoms. *J Allergy Clin Immunol* 2000; 105:951-959.
45. Jujo K, Renz H, Abe J, Gelfand EW, Leung DY. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. *J Allergy Clin Immunol* 1992; 90:323-331.
46. Borres MP, Einarsson R, Bjorksten B. Serum levels of interleukin-4, soluble CD23 and IFN gamma in relation to the development of allergic disease during the first 18 months of life. *Clin Exp Allergy* 1995; 25:543-548.
47. Strachan DP. Hay fever, hygiene, and household size. *BMJ* 1989; 299:1259-1260.
48. Strachan DP, Taylor EM, Carpenter RG. Family structure, neonatal infection, and hay fever in adolescence. *Arch Dis Child* 1996; 74:422-426.
49. Jarvis D, Chinn S, Luczynska C, Burney P. The association of family size with atopy and atopic disease. *Clin Exp Allergy* 1997; 27:240-245.
50. Räsänen M, Laitinen T, Kaprio J, Koskenvuo M, Laitinen LA. Hay fever, asthma and number of older siblings--a twin study. *Clin Exp Allergy* 1997; 27:515-518.
51. Butland BK, Strachan DP, Lewis S, Bynner J, Butler N, Britton J. Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts. *BMJ* 1997; 315:717-721.
52. Rona RJ, Duran-Tauleria E, Chinn S. Family size, atopic disorders in parents, asthma in children, and ethnicity. *J Allergy Clin Immunol* 1997; 99:454-460.

53. Strachan DP, Harkins LS, Johnston ID, Anderson HR. Childhood antecedents of allergic sensitization in young British adults. *J Allergy Clin Immunol* 1997; 99:6-12.
54. Bodner C, Anderson WJ, Reid TS, Godden DJ. Childhood exposure to infection and risk of adult onset wheeze and atopy. *Thorax* 2000; 55:383-387.
55. Farooqi IS, Hopkin JM. Early childhood infection and atopic disorder. *Thorax* 1998; 53:927-932.
56. Wickens KL, Crane J, Kemp TJ, Lewis SJ, D'Souza WJ, Sawyer GM et al. Family size, infections, and asthma prevalence in New Zealand children. *Epidemiology* 1999; 10:699-705.
57. Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. *BMJ* 2001; 322:390-395.
58. Seddon B, Mason D. The third function of the thymus. *Immunol.Today* 2000;21: 95-99.
59. Antigen-specific regulatory T cells develop *via* the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. *Nature Med* 2002.
60. Aickin R, Hill D, Kemp A. Measles immunisation in children with allergy to egg. *BMJ* 1994; 309:223-225.
61. Schmidt-Weber CB, Blaser K. Immunological mechanisms in specific immunotherapy. *Springer Semin Immunopathol* 2004;25:377-390.
62. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma: an epidemic of dysregulated immunity. *Nat Immunol* 2002;3:715-720.
63. Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, editors. *Vaccines*. Philadelphia, PA, USA: Elsevier, 2004: 1-15.
64. Ada G. Vaccines and vaccination. *New Engl J Med* 2001;345:1042-1053.
65. Empfehlungen der Ständigen Impfkommision (STIKO) am Robert-Koch-Institut. *Epid Bull* 2006;30:235-254.
66. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB et al. Risk of anaphylaxis after vaccination of children and adolescents. *Pediatrics* 2003; 112:815-820.
67. Weibel RE, Caserta V, Benor DE, Evans G. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. *Pediatrics* 1998; 101:383-387.

68. Begg N, Cutts FT. The role of epidemiology in the development of a vaccination programme. *Vaccination and world health*. Chichester, England: John Wiley, 1995: 123-138.
69. Heininger U. An internet-based survey on parental attitudes towards immunization. *Vaccine* 2006;24:6351-6355.
70. Holt PG, Rowe J, Loh R, Sly PD. Developmental factors associated with risk for atopic disease: implications for vaccine strategies in early childhood. *Vaccine* 2003;21:3432-3435.
71. Matricardi PM, Yazdanbakhsh M. Mycobacteria and atopy, 6 years later: a fascinating, still unfinished, business. *Clin Exp Allergy* 2003;33:717-720.
72. Tulic MK, Wale JL, Holt PG, Sly PD. Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. *Am J Respir Cell Mol Biol* 2000;22:604-612.
73. Grüber C. Childhood immunisations and the development of atopic disease. *Arch Dis Child* 2005;90:553-555.
74. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. *Eur J Immunol* 1996;26:1489-1496.
75. Rowe J, Macaubas C, Monger TM, Holt BJ, Harvey J, Poolman JT et al. Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. *Infect Immun* 2000;68:3873-3877.
76. Lindsay DS, Parton R, Wardlaw AC. Adjuvant effect of pertussis toxin on the production of anti-ovalbumin IgE in mice and lack of direct correlation between PCA and ELISA. *Int Arch Allergy Immunol* 1994; 105:281-288.
77. Pauwels R, Van der SM, Platteau B, Bazin H. The non-specific enhancement of allergy. I. In vivo effects of *Bordetella pertussis* vaccine on IgE synthesis. *Allergy* 1983; 38:239-246.
78. Munoz JJ, Arai H, Bergman RK, Sadowski PL. Biological activities of crystalline pertussigen from *Bordetella pertussis*. *Infect Immun* 1981; 33:820-826.
79. Ishizaka K, Iwata M, Akasaki M, Ishizaka T, Munoz JJ. Biochemical basis of the adjuvant effects of pertussis toxin for the IgE response. In: Sekura RD, Moss J, Vaughan N (Hrsg.). *Pertussis toxin*. Orlando: Academic Press, 1985: 185-204.
80. Hedenskog S, Björkstén B, Blennow M, Granström G, Granström M. Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine. *Int Arch Allergy Appl Immunol* 1989; 89:156-161.

81. Wirsing von Koenig CH, Finger H. Specific IgE-antibodies to *Bordetella pertussis* antigens during whooping cough. Lancet 1989;1:728.
82. Alm JS, Swartz J, Lilja G, Scheynius A, Pershagen G. Atopy in children of families with an anthroposophic lifestyle. Lancet 1999; 353:1485-1488.
83. Haus M, Weinberg EG. Specific IgE antibodies to *Bordetella pertussis* after immunisation in infancy. Lancet 1988; 1:1393.
84. Odelram H, Granström M, Hedenskog S, Duchén K, Björkstén B. Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines. Pediatr Allergy Immunol 1994; 5:118-123.
85. Mark A, Björkstén B, Granström M. Immunoglobulin E and G antibodies two years after a booster dose of an aluminium-adsorbed or a fluid DT vaccine in relation to atopy. Pediatr Allergy Immunol 1997; 8:83-87.
86. Duchén K, Granström M, Hedenskog S, Blennow M, Björkstén B. Immunoglobulin E and G responses to pertussis toxin in children immunised with adsorbed and non-adsorbed whole cell pertussis vaccines. Vaccine 1997; 15:1558-1561.
87. Dannemann A, van Ree R, Kulig M, Bergmann RL, Bauer P, Forster J et al. Specific IgE and IgG4 immune responses to tetanus and diphtheria toxoid in atopic and nonatopic children during the first two years of life. Int Arch Allergy Immunol 1996; 111:262-267.
88. Mark A, Björkstén B, Granström M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 1995; 13:669-673.
89. Nilsson L, Grüber C, Granström M, Björkstén B, Kjellman NI. Pertussis IgE and atopic disease. Allergy 1998; 53:1195-1201.
90. Schuster A, Hofmann A, Reinhardt D. Does pertussis infection induce manifestation of allergy? Clin Investig 1993; 71:208-213.
91. Torre D, Issi M, Chelazzi G, Fiori GP, Sampietro C. Total serum IgE levels in children with pertussis. Am J Dis Child 1990; 144:290-291.
92. Wjst M, Dold S, Reitmeir P, Fritsch C, von Mutius E, Thiemann HH. Pertussis infection and allergic sensitization. Ann Allergy 1994;73:450-454.
93. Nilsson L, Kjellman NI, Björkstén B. Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Arch Pediatr Adolesc Med 2003; 157:1184-1189.
94. Shaheen SO, Aaby P, Hall AJ, et al. Measles and atopy in Guinea-Bissau. Lancet 1996;347:1792-1796.

95. Nilsson L, Kjellman NI, Björkstén B. A randomized controlled trial of the effect of pertussis vaccines on atopic disease. *Arch Pediatr Adolesc Med* 1998;152:734-738.
96. Odent MR, Culpin EE, Kimmel T. Pertussis vaccination and asthma: is there a link? *JAMA* 1994; 272: 592-593.
97. Kemp T, Pearce N, Fitzharris P, Crane J, Fergusson D, George I, et al. Is infant immunization a risk factor for childhood asthma or allergy? *Epidemiology* 1997; 8:678-680.
98. Hurwitz EL. Universal childhood vaccinations: a Faustian bargain? *Arch Pediatr Adolesc Med* 2000; 154:1063-1064.
99. Nilsson L, Kjellman NI, Storsaeter J, Gustafsson L, Olin P. Lack of association between pertussis vaccination and symptoms of asthma and allergy. *JAMA* 1996; 275:760.
100. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, Ricci M, Romagnani S. Purified protein derivate of *Mycobacterium tuberculosis* and excretory-secretory antigen(s) of *Toxocara canis* expand *in vitro* human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. *J Clin Invest* 1991; 88: 346-350.
101. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, De Groote D, Corrah T, Bennett S, Wheeler J, Huygen K, Aaby P, McAdam KP, Newport MJ. Newborns develop a Th1-type immune response to *Mycobacterium bovis* bacillus Calmette-Guérin vaccination. *J Immunol* 1999; 163: 2249-2255.
102. Sander B, Skansen-Saphir U, Damm O, Hakansson L, Andersson J, Andersson U. Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guérin. *Immunology* 1995; 86: 512-518.
103. Flesch IE, Kaufmann SH. Activation of tuberculostatic macrophage functions by gamma interferon, interleukin 4, and tumor necrosis factor. *Infect Immun* 1990; 58: 2675-2677.
104. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to *Mycobacterium tuberculosis* infection. *J Exp Med* 1993; 178: 2249-2254.
105. Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G. Infection of mice with *Mycobacterium bovis*-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. *J Exp Med* 1998; 187:561-569.
106. Herz U, Gerhold K, Grüber C, Braun A, Wahn U, Renz H et al. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. *J Allergy Clin Immunol* 1998; 102; 867-874.

107. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed *Mycobacterium vaccae*. *Immunology* 1998; 93:307-313.
108. von Mutius E, Pearce N, Beasley R, Cheng S, von Ehrenstein O, Bjorksten B et al. International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema. *Thorax* 2000; 55:449-453.
109. Shirtcliffe P, Weatherhall M, Beasley R; International Study of Asthma and Allergies in Childhood. An inverse correlation between estimated tuberculosis notification rates and asthma symptoms. *Respirology* 2002; 7: 153-155.
110. von Hertzen L, Klaukka T, Mattila H, Haahtela T. *Mycobacterium tuberculosis* infection and the subsequent development of asthma and allergic conditions. *J Allergy Clin Immunol* 1999; 104:1211-1214.
111. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. *Science* 1997; 275:77-79.
112. Aalberse RC, van Ree R, Danneman A, Wahn U. IgE antibodies to tetanus toxoid in relation to atopy. *Int Arch Allergy Immunol* 1995; 107:169-171.
113. Olesen AB, Juul S, Thestrup-Pedersen K. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection. *Acta Derm Venereol* 2003; 83:445-450.
114. Rook GA, Stanford JL. Give us this day our daily germs. *Immunol Today* 1998; 19:113-116.
115. Taylor-Robinson AW. Multiple vaccination effects on atopy. *Allergy* 1999; 54:398-400.
116. Jefferson T. Vaccination and its adverse effects: real or perceived. Society should think about means of linking exposure to potential long term effect. *BMJ* 1998; 317:159-160.
117. Measles immunisation non-acceptance: validation of computer-held records and raising the vaccine uptake at early school age; the Maidenstone experience. *Public Health* 1989; 103: 289-294.
118. Bergmann RL, Bergmann KE, Lau-Schadendorf S, Luck W, Dannemann A, Bauer CP et al. Atopic diseases in infancy. The German multicenter atopy study (MAS-90). *Pediatr Allergy Immunol* 1994; 5(6 Suppl):19-25.
119. Grüber C, Illi S, Lau S, Nickel R, Forster J, Kamin W et al. Transient suppression of atopy in early childhood is associated with high vaccination coverage. *Pediatrics* 2003; 111:e282-e288.
120. Grüber C, Illi S, Plieth A, Sommerfeld C, Wahn U. Cultural adaptation is associated with atopy and wheezing among children of Turkish origin living in Germany. *Clin Exp Allergy* 2002; 32:526-531.

121. Grüber C, Meinlschmidt G, Bergmann R, Wahn U, Stark K. Is early BCG vaccination associated with less atopic disease? An epidemiological study in German preschool children with different ethnic backgrounds. *Pediatr Allergy Immunol* 2002; 13:177-181.
122. Grüber C, Kulig M, Bergmann R, Guggenmoos-Holzmann I, Wahn U. Delayed hypersensitivity to tuberculin, total immunoglobulin E, specific sensitization, and atopic manifestation in longitudinally followed early Bacille Calmette-Guerin-vaccinated and nonvaccinated children. *Pediatrics* 2001; 107:e36.
123. Grüber C, Lau S, Dannemann A, Sommerfeld C, Wahn U, Aalberse RC. Down-regulation of IgE and IgG4 antibodies to tetanus toxoid and diphtheria toxoid by covaccination with cellular *Bordetella pertussis* vaccine. *J Immunol* 2001; 167:2411-2417.
124. Grüber C, Gerhold K, von Stuckrad SL, Avagyan A, Quarcoo D, Ahrens B et al. Common vaccine antigens inhibit allergen-induced sensitization and airway hyperresponsiveness in a murine model. *Allergy* 2006; 61:820-827.
125. Grüber C, Nilsson L, Björkstén B. Do early childhood immunizations influence the development of atopy and do they cause allergic reactions? *Pediatr Allergy Immunol* 2001; 12:296-311.
126. Holt PG, Rudin A, Macaubas C, Holt BJ, Rowe J, Loh R et al. Development of immunologic memory against tetanus toxoid and pertactin antigens from the diphtheria-tetanus-pertussis vaccine in atopic versus nonatopic children. *J Allergy Clin Immunol* 2000; 105:1117-1122.
127. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. *J Allergy Clin Immunol* 1999; 103:321-325.
128. Ryan EJ, Nilsson L, Kjellman N, Gothefors L, Mills KH. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. *Clin Exp Immunol* 2000; 121:193-200.
129. Aaby P, Shaheen SO, Heyes CB, Goudiaby A, Hall AJ, Shiell AW et al. Early BCG vaccination and reduction in atopy in Guinea-Bissau. *Clin Exp Allergy* 2000; 30:644-650.
130. Anderson HR, Poloniecki JD, Strachan DP, Beasley R, Björkstén B, Asher MI. Immunization and symptoms of atopic disease in children: results from the International Study of Asthma and Allergies in Childhood. *Am J Public Health* 2001; 91:1126-1129.
131. Grüber C, Paul K. Tuberculin reactivity and allergy. *Allergy* 2002;57:277-280.

132. Grüber C, Paul KP. Schützen Mykobakterien vor Asthma und Allergie? Mschr Kinderheilkd 2002; 150: 1497-1501.
133. Arkwright PD, David TJ. Intradermal administration of a killed *Mycobacterium vaccae* suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001; 107:531-534.
134. Arkwright PD, David TJ. Effect of *Mycobacterium vaccae* on atopic dermatitis in children of different ages. Br J Dermatol 2003; 149:1029-1034.
135. Shirtcliffe PM, Easthope SE, Cheng S, Weatherall M, Tan PL, Le Gros G et al. The effect of delipidated deglycolipidated (DDMV) and heat-killed *Mycobacterium vaccae* in asthma. Am J Respir Crit Care Med 2001; 163:1410-1414.
136. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann Allergy Asthma Immunol 2002;88:584-591.
137. Choi IS, Koh YI. Effects of BCG revaccination on asthma. Allergy 2003; 58:1114-1116.
138. Zuany-Amorim C, Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed *Mycobacterium vaccae* in a murine model of allergic pulmonary inflammation. J Immunol 2002; 169:1492-1499.
139. Zuany-Amorim, Manlius C, Trifilieff A, et al. Long-term protective and antigen-specific effect of heat-killed *Mycobacterium vaccae* in a murine model of allergic pulmonary inflammation. J Immunol 2002; 169:1492-99.
140. Adams VC, Hunt JR, Martinelli R, et al. *Mycobacterium vaccae* induces a population of pulmonary CD11c+ cells with regulatory potential in allergic mice. Eur J Immunol 2004; 34:631-634.
141. Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener RP, Schmidt-Weber CB, Klunker S, Isitmangil G, Hansjee N, Wynn TA, Dillon S, Erb P, Baschang G, Blaser K, Alkan SS. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003; 33:2717-2726.
142. Barlan IB, Bahceciler N, Akdis M, Akdis CA. Role of bacillus Calmette-Guerin as an immunomodulator for the prevention and treatment of allergy and asthma. Curr Opin Allergy Clin Immunol 2005; 5: 552-557.
143. Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH. *Bordetella pertussis* respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 1997; 175:1246-1250.
144. Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gothefors L et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998; 93:1-10.

145. Holt PG, Sly PD, Martinez FD, et al. Drug development strategies for asthma: in search of a new paradigm. *Nat Immunol* 2004;5:695-698.
146. Rook GA, Adams V, Hunt J, et al. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. *Springer Semin Immunopathol* 2004;25:237-255.
147. Grüber C. Haben Impfungen einen protektiven oder einen akzelerierenden Einfluss auf Allergien? *PädiatPrax* 2005; 66: 453-458.
148. Grüber C. Leitlinien der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin: Impfung allergischer Kinder. *Pädiatrische Allergologie* 2003;6:14-15.
149. Grüber C, Niggemann B. A practical approach to immunization in atopic children. *Allergy* 2002; 57:472-479.